NOT KNOWN FACTUAL STATEMENTS ABOUT ABBV-744

Notwithstanding many setbacks, several MDM2 inhibitors have now progressed into late-phase scientific development. New tactics have also been designed to improve the efficacy of MDM2 inhibitors and to mitigate their on-goal toxicity. Within this evaluation, we summarize the progress and difficulties in the development of a MDM2 targeted therapy.Ind